U.S. Organ Transplant Pharmaceuticals Markets

Published by: Frost & Sullivan

Published: Aug. 1, 2002

Table of Contents

1 Executive Summary

A. Executive Summary

1 Executive Summary

2 Total Market

A. Overview

1 The Immune System and Organ Transplant Rejection

2 The History of Organ Transplant Immunosuppression

3 The Nature of the Market

4 Report Scope and Segmentation

B. Market Dynamics

1 Challenges

2 Drivers

3 Restraints

4 Market Engineering Analysis

C. Forecasts and Trends

1 Market and Technology Trends

2 Revenue Forecasts

3 Market Share Analysis

D. Strategic Recommendations

1 Strategic Recommendation 1

2 Strategic Recommendation 2

3 Strategic Recommendation 3

E. Market Engineering Awards

1 Product Line Strategy - Novartis Pharmaceutical Corporation

2 Technology Innovation - Isotechnika Inc.

3 Market Penetration - Roche Laboratories

4 Product Innovation - SangStat Medical Corporation

5 Competitive Strategy Award- Abbott Laboratories

3 Solid Organ Transplant Demand and Supply Analysis

A. Total Demand and Supply Analysis

1 Overview

B. Demand and Supply Analysis by Organ Type

1 Kidney Transplants

2 Liver Transplants

3 Heart Transplants

4 Lung Transplants

5 Pancreatic Transplants

6 Intestinal Transplants

7 Combined Organ Transplants

4 U.S. Chronic Immunosuppressant Therapies Market

A. Overview

1 Introduction

2 Market and Technology Trends

3 Market Engineering Analysis

B. Forecasts and Trends

1 Revenue Forecasts

2 Revenue Forecast Assumptions

3 Market Share Analysis

4 Demand Analysis

5 Pricing Trends

C. Competitive Analysis

1 Product Analysis - Calcineurin Inhibitors

2 Product Analysis - TOR Inhibitors

3 Product Analysis - Antimetabolites

4 Product Analysis - Corticosteroids

5 Competitive Structure

D. Emerging Technologies

1 Biotechnology Trends

2 Product Pipeline

5 U.S. Acute Immunosuppressant Therapies Market

A. Overview

1 Introduction

2 Market and Technology Trends

3 Market Engineering Analysis

B. Forecasts and Trends

1 Revenue Forecasts and Assumptions

2 Market Share Analysis

3 Demand Analysis

4 Pricing Trends

C. Competitive Analysis

1 Product Analysis - Prophylactic Agents

2 Product Analysis - Acute Rejection Episode Treatment Agents

3 Comparative Studies

4 Competitive Structure

5 Product Pipeline

Abstract

Impressive developments in the field of transplant immunosuppression therapies have given rise to high expectations of revolutionary solutions in the near future. New side-effect sparing chronic immunosuppressive drugs and prophylactic uses of acute immunosuppressive therapies such as monoclonal and polyclonal antibodies are making transplantation one of the most successful and promising areas of medicine.

This Frost & Sullivan research on the U.S. Organ Transplant Pharmaceuticals Markets spans the most important aspects of the solid organ transplant market - research and development (R&D) products, top competitors, demand and revenue forecasts from 1998 to 2008, challenges and opportunities, and technology trends. This study covers chronic and acute immunosuppressants markets.

Improved Survival Rates and New Patient Groups Provide Market Opportunity

Since the advent of organ transplants, survival rates of transplant recipients have improved, and, it is expected that there will be a sustained demand for improved anti-rejection pharmaceuticals. Also, a rise in organ transplants that were previously rare, such as those of the intestines, lung, and kidney-pancreas, intensify the demand for improved immunosuppressants. Adverse side-effect profiles weigh down on many of the current therapeutics providing pharmaceutical companies tremendous initiative to develop drugs that are safer and more effective.

Prospective markets lie in new patient groups such as children, pregnant women, and ethnic groups, whose immune system may require different doses/types of immunosuppression. As well, currently marketed products may opt to seek FDA approval for use in additional types of transplants. "The opportunity for expanded indications across the organ transplant field creates profit potentials for anti-rejection pharmaceuticals," says the analyst.

Prophylactic Use of Immunosuppressants Contributes to Revenues

According to the author, "In acute immunosuppression markets, there is a trend towards increasing prophylactic use of monoclonal and polyclonal antibodies." Superior efficacy and long-term improvements in organ transplant outcomes are factors that are more important than price in this market. Therefore, this market is quality-driven rather than price-driven.

With several ongoing research and development projects for both chronic and acute immunosuppressants, the market can expect the introduction of innovative products that will offer clinical solutions to some of the currently unmet market needs.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.